NCT03371017
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, untreated, or actively progressing central nervous system (CNS) metastases; Patients with a history of leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03371017